Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeiGene
Marketing
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
The average wholesale acquisition cost of Tevimbra is estimated to be $15,075 per month, a BeiGene spokesperson told Fierce Pharma.
Angus Liu
Oct 4, 2024 10:37am
Experts back FDA's plan to restrict PD-1 drugs in GI cancers
Sep 26, 2024 1:38pm
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Sep 13, 2024 8:53am
BeiGene takes top sponsorship spot as lymphoma campaign ramps up
Sep 5, 2024 8:00am
Sanofi, DualityBio, UCB—Fierce Pharma Asia
Aug 30, 2024 8:05am
